Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: a high potency effect of clozapine
HY Meltzer, J Kennedy, J Dai, M Parsa… - …, 1995 - Elsevier
The purpose of this study was to determine the plasma level of clozapine and its metabolite,
N-desmethylclozapine, in Parkinson's disease patients with L-DOPA-induced psychosis
responsive to clozapine. The psychotic symptoms of the three patients studied responded to
low doses of clozapine with plasma levels of clozapine between 4.5 and 16.1 ng/ml and N-
desmethylclozapine between 2.6 and 6.1 ng/ml, much below the plasma clozapine levels
usually found in clozapine-treated refractory schizophrenia or affective disorders (range 100 …
N-desmethylclozapine, in Parkinson's disease patients with L-DOPA-induced psychosis
responsive to clozapine. The psychotic symptoms of the three patients studied responded to
low doses of clozapine with plasma levels of clozapine between 4.5 and 16.1 ng/ml and N-
desmethylclozapine between 2.6 and 6.1 ng/ml, much below the plasma clozapine levels
usually found in clozapine-treated refractory schizophrenia or affective disorders (range 100 …